Safety of administration of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, before curative-intent treatment in patients with HPV16+ oropharyngeal squamous cell carcinoma.
Sidharth V. Puram(Washington University in St. Louis), Douglas R. Adkins(Washington University in St. Louis), Jason T. Rich(Washington University in St. Louis), Nikhil Ram-Mohan(Stanford University), Jingxia Liu(Washington University in St. Louis), Anthony J. Apicelli(Washington University in St. Louis), R. Alex Harbison(Washington University in St. Louis), Matteo Levisetti, Patrik Pipkorn(Washington University in St. Louis), Anish Suri(Bristol-Myers Squibb (United States)), Michael J. Moravan(Duke Medical Center), Wade L. Thorstad(Washington University in St. Louis), Jennifer De Los Santos(University of Alabama at Birmingham), Jesse M. Zaretsky(Washington University in St. Louis), Steven N. Quayle(CTI BioPharma (Italy)), Jessica Ley(Washington University in St. Louis), Michael Atteberry(Washington University in St. Louis), Ryan S. Jackson(Washington University in St. Louis)
Cited by 4
Related Papers
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
|New England Journal of Medicine|2016|3.1k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k